Latest Commercialization News

Acrux Limited spotlighted its Female Testosterone Metered Dose Transdermal System (MDTS) at the Bioshares Biotech Summit, revealing positive Phase II data and outlining a clear regulatory and commercial roadmap targeting Hypoactive Sexual Desire Disorder (HSDD) in women.

Osteopore has inked a three-year distribution agreement with Al-Umnia Medical to bring its 3D-printed orthopaedic implants to five Gulf countries, targeting a rapidly expanding regional market.

Nex Metals has advanced its Kookynie Tailings Project metallurgical testing, lifting gold recovery significantly and uncovering a promising tungsten by-product opportunity.

ClearVue Technologies has secured Clean Energy Council approval for its ClearVue-Helios rooftop solar panels, enabling government subsidies and grid connection in Australia. This certification coincides with expanded commercial solar incentives, potentially lowering costs for customers.

Dimerix CEO Dr Nina Webster detailed the company’s geographic and product diversification at the Bioshares Summit, spotlighting the commercial potential of DMX-200 and the newly acquired Phase 2 asset DMX-652 targeting acute kidney injury.

REA Group Ltd (ASX:REA) posted a robust FY26 with revenue up 7% to A$1.793 billion and core net profit rising 15% to A$682 million, supported by record audience engagement and strategic AI investments.

Alliance Aviation Services has secured a materially improved wet lease agreement with Qantas, including higher pricing and a fleet reduction, while reaffirming its FY26 profit guidance amid operational realignment.

Sky Metals has voluntarily suspended its ASX-listed securities pending a material announcement regarding its Tallebung Tin-Tungsten-Silver Project, with trading expected to resume by 10 August or upon release of the news.

Clarity Pharmaceuticals reveals encouraging early results from the SECuRE trial, with substantial PSA reductions and multiple complete responses at the 8 GBq 67Cu-SAR-bisPSMA dose level in advanced prostate cancer patients.

Neuren Pharmaceuticals saw a record Q2 with DAYBUE net sales hitting US$125 million, driven by strong uptake of the new STIX formulation. The company upgraded its 2026 royalty guidance following Acadia Pharmaceuticals’ sales boost and awaits key regulatory milestones in Europe and Japan.

Ionic Rare Earths (ASX: IXR) has secured $8 million through a placement to back its Belfast Plant commercialisation and US growth plans, supported by a mix of domestic and international investors including a strategic US partner.

Spacetalk Ltd has locked in $10 million through a two-tranche share placement, aiming to fund platform enhancements, inventory growth, and a major network migration.